New lupus drug CUG252 passes first safety check in small trial
Disease control
Completed
This early-phase study tested the safety of a new drug, CUG252, in 40 adults with mild-to-moderate systemic lupus erythematosus (SLE). Participants received multiple doses of the drug or a placebo by injection. The main goal was to see if the drug is safe and tolerable, and to un…
Phase: PHASE1 • Sponsor: Cugene Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC